BMS’ Krazati Receives the US FDA’s Accelerated Approval to Treat Locally Advanced or Metastatic Colorectal Cancer (mCRC)
Shots:
- BMS’ Krazati (KRASG12C inhibitor) in addition to cetuximab has received the US FDA’s accelerated approval to treat locally advanced or metastatic colorectal cancer (mCRC) associated with KRASG12C-mutation. Full approval depends upon confirmatory studies
- The approval was supported by a P-I/II (KRYSTAL-1) study assessing the safety & efficacy of Krazati (600mg, oral, BID) + cetuximab to treat heavily pretreated patients (n=94) with mCRC having a KRASG12C mutation
- The study reached its 1EP, demonstrating a confirmed ORR of 34% (all were PRs) and a mDoR (2EP) of 5.8mos.
Ref: BMS | Image: BMS
Related News:- BMS Reports the EMA’s Validation of the Application for Subcutaneous Opdivo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
